Winst gevend schreef op 29 oktober 2022 21:26:
.
.
Sijmen de Vries"And then, of course, you see there below that in itself, we believe
that the leniolisib compound could become a platform in itself
because we have found some very interesting additional indications
from research alliances that
Novartis has been doing
with several very renowned institutions and are currently sort of
prioritizing which one of these diseases to prioritize for subsequent development
and of course, bring them eventually to the markets."
.
.
Anurag Relan"So we are looking at additional indications for leniolisib.
These are not actually in the area of other primary immune deficiencies,
but we are looking at a number of indications.
And as Sijmen mentioned, these include areas where
Novartis had actually started
some work and has already some research collaborations ongoing.
So we're trying to leverage that.
But we're also looking at some new areas.
I don't think we're ready yet to disclose what those areas are today.
But as soon as we make some more progress with this,
and I think we'll be able to talk about that in the near future,
which specific areas these include."